(Q28298312)

https://api.crossref.org/works/10.2146%2FAJHP070628

Chemotherapy: what progress in the last 5 years?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Molecular mechanisms of drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Adjuvant and neoadjuvant therapy in non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Epothilones in breast cancer: review of clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Epothilones in prostate cancer: review of clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Potential clinical applications of epothilones: a review of phase II studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

The chemistry and biology of epothilones--the wheel keeps turning.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Novel agents that target tublin and related elements

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Ixabepilone and the narrow path to developing new cytotoxic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Peripheral neuropathy induced by microtubule-stabilizing agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Management of toxicities associated with the administration of taxanes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628

Management and preparedness for infusion and hypersensitivity reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070628